SAN FRANCISCO, May 3— The wife of Genentech's chief executive officer is the focus of an insider trading investigation being conducted by the Securities and Exchange Commission, the company disclosed today. The investigation …
Curis' revenue for Q4 FY17 mainly included royalty revenues recorded on Genentech and Roche's net sales of Erivedge ... the end of FY17 compared to $19.86 million at the end of FY16. Stock Performance Snapshot April 18, 2018 - At …
GlaxoSmithKline signalled its intention to boost its drug pipeline through deals by hiring Kevin Sin from Roche’s Genentech unit to lead a worldwide ... and list its Etiqa insurance arm on the local stock exchange, sources with …
But the only Apple employee to make the cut is chairman Art Levinson, and as …
NEW YORK (CNNMoney.com) - Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006. The biotech, based in South San Francisco, also said it expects to …
In December, the U.S. Food and Drug Administration greenlighted Ogivri, a …
SAN FRANCISCO, April 3— Shares of Genentech Inc. rose 5.6 percent today after the biotechnology company said the Food and Drug Administration had approved a faster intravenous regimen for Activase, the company's heart-attack drug …
Since Roche announced its intention to buy the outstanding shares of Genentech, everbody’s been wondering whether the company’s top scientists will bolt. Genentech put a retention plan in place yesterday — but the main payouts would …
In December, the U.S. Food and Drug Administration greenlighted Ogivri, a biosimilar, or copy, of Roche Group RHHBY unit Genentech's Herceptin ... down 2.7%. The stock is down 4.5% year-to-date but up 5.1% over the last 12 months. …
said it settled litigation with Genentech and Tercica regarding the growth-deficiency treatment Iplex, and will have to slash its work force as a result. Insmed's (down $0.60 to $0.95, Charts) stock price plunged 46 percent following the news. …